Halozyme Therapeutics Showcases ENHANZE® Innovations at September Investor Conferences

Halozyme Therapeutics Showcases Innovations in Drug Delivery Technology at Upcoming Investor Conferences

Halozyme Therapeutics, Inc. is set to highlight its pioneering advancements in drug delivery technology during a series of investor conferences in September 2025. Dr. Helen Torley, President and CEO, along with Tram Bui, VP of Investor Relations and Corporate Communications, will engage with investors at notable events, including the Wells Fargo Healthcare Conference in Boston and the Morgan Stanley Annual Global Healthcare Conference in New York. Their participation underscores Halozyme's commitment to fostering transparency and collaboration within the biopharmaceutical sector. The company aims to connect with stakeholders about its innovative ENHANZE® drug delivery technology, which has transformed treatment protocols across various therapeutic areas.

Halozyme's ENHANZE® technology, leveraging the proprietary enzyme rHuPH20, allows for the subcutaneous delivery of injected drugs and fluids. This delivery method not only enhances the patient experience by expediting treatment but also alleviates the logistical burdens associated with traditional intravenous methods. By streamlining the administration of therapies, Halozyme has made a significant impact on over one million patients worldwide through its licensed technology, utilized in ten commercialized products across more than 100 global markets. This extensive reach reflects the vital role of ENHANZE® in modern medicine, particularly in improving patient adherence and satisfaction.

The company's strategic partnerships with major pharmaceutical players, including Roche, Takeda, and Pfizer, demonstrate its robust position in the industry. Halozyme's involvement in developing and commercializing drug-device combinations, both independently and in collaboration with partners, further cements its reputation as an innovator in the biopharmaceutical landscape. As the upcoming investor conferences approach, Halozyme's leadership aims to share insights into their growth strategy while emphasizing the transformative potential of their technology in enhancing therapeutic outcomes.

In addition to the live presentations scheduled for September, Halozyme will provide an audio webcast of the discussions, allowing broader access to their insights. Replays will be available for 90 days after the conferences, ensuring that stakeholders have the opportunity to engage with the content at their convenience. This proactive approach to investor relations illustrates Halozyme's dedication to keeping its community informed and connected to its ongoing advancements in drug delivery solutions.

As Halozyme Therapeutics continues to lead in innovative drug delivery systems, its participation in these conferences serves as an important platform for dialogue and collaboration, ultimately aiming to enhance the delivery of critical therapies to patients around the globe.